Antibody-mediated neutralization may interfere with the efficacy of measles virus (MV) oncolysis. To circumvent vector neutralization, we sought to exchange the envelope glycoproteins, hemagglutinin (H) and fusion (F), with those from the noncrossreactive Tupaia paramyxovirus (TPMV). To sustain efficient particle assembly, we generated hybrid glycoproteins with the MV cytoplasmic tails and the TPMV ectodomains. Hybrid F proteins that partially retained fusion function, and hybrid H proteins that retained fusion support activity, were generated. However, when used in combination, the hybrid proteins did not support membrane fusion. An alternative strategy was developed based on a hybrid F protein and a truncated H protein that supported cell-cell fusion. A hybrid virus expressing these two proteins was rescued, and was able to spread by cell fusion; however, it was only capable of producing minimal amounts of particles. Lack of specific interactions between the matrix and the H protein, in combination with suboptimal F-protein processing and inefficient glycoprotein transport in the rescue cells, accounted for inefficient particle production. Ultimately, this interferes with applications for oncolytic virotherapy. Alternative strategies for the generation of shielded MV are discussed.
INTRODUCTION
Several viruses, including Adeno-, Herpes-, Pox-, Reo-and Paramyxoviridae, are being tested in clinical trials for the treatment of various tumors, 1, 2 and an oncolytic adenovirus is currently an approved cancer therapeutic in China. 3 However, the high prevalence of pre-existing antibodies against many vectors may reduce or eliminate their oncolytic efficacy. This issue has been addressed by exchanging the envelope, or capsid, of different viruses with those of non-crossreactive serotypes. 4, 5 Measles virus (MV), one of the most promising oncolytic viruses, is currently used in phase I clinical trials to treat glioblastoma multiforme, multiple myeloma and ovarian cancer. 1, [6] [7] [8] Unlike other viruses, such as vesicular stomatitis virus and adenoviruses, MV has a single serotype. 9 Therefore, a novel serotype was engineered based on the glycoprotein complex (the fusion (F) and hemagglutinin (H) proteins) from a related but nonimmunologically crossreactive Morbillivirus. 10 This shielded MV remained oncolytic in an immunocompetent mouse model even in the presence of anti-MV neutralizing antibodies. 10 However, antibodies against the new envelope of the shielded MV will eventually be generated.
To allow for sequential cycles of virotherapy, additional shielding envelopes will need to be developed. Here, we investigated the suitability of the envelope glycoproteins from the Tupaia paramyxovirus (TPMV), 11, 12 a close relative of the Morbillivirus genus. Although a direct exchange of the canine distemper virus and MV glycoproteins was possible, 10 our initial attempts to rescue a hybrid MV with the TPMV glycoproteins were unsuccessful (C Springfeld and R Cattaneo, unpublished). Knowing that efficient MV particle assembly depends on the interaction between the matrix protein and the cytoplasmic tails of the glycoproteins, 13, 14 and that the TPMV glycoprotein cytoplasmic tails are not homologous to the MV glycoprotein cytoplasmic tails, we then sought to generate hybrid glycoproteins. As the cytoplasmic tails of the TPMV glycoproteins are not characterized, we first generated truncation mutants and assessed fusion function. Based on these data, we generated hybrid glycoproteins with a TPMV ectodomain and the corresponding MV cytoplasmic tail. When associated with the wild-type partner, these hybrid glycoproteins retained high levels of fusion competency. However, in combination, hybrid F and H proteins no longer supported fusion.
On the other hand, the combination of a hybrid F protein and a cytoplasmic tail-truncated TPMV H protein sustained fusion function. A hybrid virus with these two proteins in place of MV F and H spread through cell-cell fusion, but failed to efficiently produce particles. We therefore sought to determine the factors influencing hybrid virus assembly by determining glycoprotein surface expression, transport and processing kinetics. We show that reduced hybrid F-protein processing and suboptimal transport of glycoproteins in the virus producer cell line contribute to inefficient particle formation. 
Plasmids
The plasmid pCG-IRESzeo was used for the expression of all deletion and chimeric glycoproteins. 19 The TPMV F and H cDNA were cloned from infected tupaia baby fibroblast cells using the following primers: BamHI-Ff
0 ) and H6-PacIHr (5 0 -AGCA GCATGCTTAATTAATTAGTGGTGGTGGTGGTGGTGCTTAGTATTAGGACATG-3 0 ) (restriction sites are underlined) using the reverse transcriptase Superscript III (Invitrogen). DNAs coding for hybrid glycoproteins were generated by overlap extension polymerase chain reaction. Sequence-verified clones were used to replace the F and H open reading frames in the full-length MV cDNA p( þ )MVvac2(green fluorescent protein (GFP))H, by exchange of SanDI-PacI (F)-and PacI-MluI (H)-digested fragments to generate the hybrid virus p( þ )MVvac2(FD32/mvcyt-HD90)GFP. 20 Primer sequences are available upon request.
The sequences of all glycoprotein genes, deletion mutants and hybrids were confirmed via DNA sequencing (ABI Prism 377 DNA Sequencer; Perkin-Elmer Applied Biosystem, Waltham, MA, USA). Full-length plasmids coding for a genomic cDNA conform to the rule of six. 21, 22 Cells Vero-aHis (African green monkey kidney Vero cells transduced to express a membrane-bound single-chain antibody recognizing a 6 Â His-tag), 23 Vero, 293 (human embryonic kidney) and tupaia baby fibroblast 24 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (DMEM-10; Mediatech, Manassas, VA, USA), and 293-3-46 (MV rescue helper cell line) 25 was grown in DMEM-10 supplemented with 1.2 mg ml G418 (Invitrogen). CHO-K1 cells used in pulse-chase experiments were grown in DMEM-10 supplemented with non-essential amino acids (Mediatech). All cells were propagated at 37 1C in a 5% CO 2 humidified incubator.
Viruses
The parental MVvac2(GFP)H 20 virus and derivatives were rescued, propagated and purified as described previously. 25 Briefly, 10 mg of fulllength DNA was transfected using the ProFection (Promega, Madison, WI, USA) calcium phosphate transfection kit with 10 ng of the viral polymerase plasmid pEMC-La into 293-3-46 cells, which express the MV N and P proteins. Cells were plated at a density of 5 Â 10 5 in 35 mm dishes and 2 days post-transfection, overlaid onto Vero-aHis cells. Cytopathic effect and GFP expression was monitored. The titers of the rescued viruses were determined by log 10 50% tissue culture infective dose (TCID 50 ) as calculated by the Spearman-Kärber method. 26, 27 Virus growth kinetics Cells were infected at a multiplicity of infection (MOI) of 0.03. At various time points, supernatants (media fractions) were clarified by centrifugation and cells were scraped into Opti-MEM I Reduced Serum Media (Invitrogen). The samples were rapidly frozen and thawed. Released and cell-associated viral titers were determined by TCID 50 titration.
Fusion assays
Cell-cell fusion assays were conducted using Vero-aHis cells plated at a density of 10 5 per well in 24-well tissue culture plates. The cells were transfected using Lipofectamine 2000 (Invitrogen) with expression plasmids pCG-TPMV F and pCG-TPMV H His-tag or its deletion mutants (0.4 mg per each). A plasmid expressing the GFP (pEGFP-N1, 0.1 mg) was added to allow visualization of transfected cells. For each well, the plasmid DNAs, 2 ml of Lipofectamine 2000 and 48 ml of Opti-MEM were mixed; the mixture was let to stand for 20 min at room temperature, and then added to cells for 24 h. The extent of fusion was then recorded using the following convention: À , no syncytium; þ , 3-5 nuclei per syncytium; þ þ , 5-15 nuclei per syncytium; and þ þ þ , more than 15 nuclei per syncytium. Images were collected on a Nikon Eclipse TE300 using NIS-Elements F 3.0 software (Nikon Instruments, Melville, NY, USA). Three fields of approximately 500 cells per field were scored and averaged. The fusion scores were based on the averages of at least three independent experiments.
Immunoblotting
Vero-aHis cells were plated and transfected as described for the cell-cell fusion assay. Samples were washed three times with phosphate-buffered saline (PBS) before cytoplasmic extraction using 100 ml RIPA buffer (150 mM NaCl, 1% Igepal CA-680, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris (pH 8)) supplemented with Protease Inhibitor Cocktail Set I (Calbiochem, Rockland, MA, USA) per well at 4 1C for 5 min. The lysates were cleared by centrifugation at 21 000 g for 10 min at 4 1C. Endo-b-N-acetylglycosaminidase H (EndoH) digestion was carried out on 10 ml of cleared lysate. Protein samples were denatured using urea buffer 27 for 5 min at 95 1C before separation on SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were then transferred to polyvinylidine difluoride membranes (Immobilon-P; Millipore, Billerica, MA, USA), blocked with 5% milk in TBST (10 mM Tris (pH 8), 150 mM NaCl, 0.05% Tween-20) and subjected to enhanced chemiluminescence detection using the antibodies indicated (GE Healthcare, Waukesha, WI, USA).
FACS analysis
Cells were plated at 5 Â 10 5 per 35 mm dish and transfected as described above with 4 mg per well of either pCG-MV-H617, pCG-TPMV-H His-tag , pCG-TPMV-HD90 or the negative control plasmid peGFP-N1. At 24 h posttransfection, the cells were washed once with PBS and detached in 500 ml Versene (Gibco, Grand Island, NY, USA) and washed with FACS buffer (PBS supplemented with 5% FCS and 0.1% NaN 3 ). Samples were stained with the anti-His-specific antibody Penta-His AlexaFluor 647 (Qiagen) for 1 h at 4 1C, washed with FACS buffer and fixed with 2% paraformaldehyde in PBS. Samples were screened by the Mayo Clinic Optical Morphology Core facility and data were analyzed using FlowJo 9.4.10 software (Tree Star, Ashland, OR, USA).
Metabolic labeling, immunoprecipitation and glycosidase digestion
CHO-K1 cells plated in 35 mm dishes were transfected with 2 mg F and H His-tag or mutant protein expression plasmids. At 24 h post-transfection, cells were starved in cysteine-and methionine-deficient DMEM (Invitrogen; catalog number 21013-024) supplemented with sodium pyruvate, sodium bicarbonate and L-glutamate (DMEM ( À cys/ À met)) for 30 min, then labeled with Trans 35 S-label (100 mCi ml) (Perkin-Elmer) in DMEM -cys/-met for 1 h at 37 1C and chased with unlabeled DMEM-10 for the times indicated. Cells were then washed with PBS and lysed with 100 ml denaturing lysis buffer (1% SDS, 50 mM Tris (pH 7.5), 5 mM EDTA (pH 8): for F proteins) or 500 ml RIPA buffer (for H proteins) supplemented with protease inhibitor (1 mM phenylmethanesulfonylfluoride and Protease Inhibitor Cocktail Set I). To expose the antigen recognized by the TPMV-F ecto antibody, F-protein samples were denatured at 99 1C for 5 min, followed by the addition of 900 ml of non-denaturing lysis buffer (1% Triton X-100, 50 mM Tris (pH 7.5), 300 mM NaCl, 0.02% sodium azide), and cell lysates were passed through a 25-G needle to shear genomic DNA. All lysates were then clarified by centrifugation for 20 min at 21 000 g.
Aliquots of protein lysate were immunoprecipitated using the antibodies indicated with protein G-agarose (Roche, Indianapolis, IN, USA) overnight at 4 1C. The samples were washed and dissociated by boiling for 5 min in 0.5% SDS and 40 mM dithiothreitol. Dissociated samples were then subjected to EndoH (NEB, Ipswich, MA, USA) digestion (20 U per sample) at 37 1C for 1 h in 50 mM sodium citrate (pH 5.5). H-protein samples were fractionated on 7.5% SDS-PAGE and F proteins were fractionated on 10% SDS-PAGE. Protein band intensities were quantified using the Typhoon FLA 7000 phosphorimaging system and ImageQuant TL software (GE Healthcare).
RESULTS

TPMV H interacts with an unknown receptor present only on
Tupaia cells. 12 Thus, to facilitate the functional analysis of hybrid proteins, we extended the TPMV H ectodomain with a 6 Â His-tag. This His-tag allows us to utilize the Vero-aHis cell line, which expresses a pseudoreceptor recognizing it. 23, 28 These cells also support the rescue of retargeted MV-based vectors. 23 TPMV F protein with six amino-acid cytoplasmic tail maintains wild-type fusion function The TPMV F-protein cytoplasmic tail is 38 amino acids in length, 5 amino acids longer than the MV F-tail, with no homology shared between the two F-tails. Towards generating a chimeric F glycoprotein, we first sought to define the minimal sequence necessary for TPMV-F fusion function. We coexpressed the F and H glycoproteins in Vero-aHis cells and observed syncytia formation (Figure 1a) . [28] [29] [30] When the TPMV F-tail was shortened in 10 amino-acid increments (Figure 1b; FD10-FD40 ), we observed that deletion of up to 30 amino acids had no effect on fusion function (Figure 1b ; FD10, FD20 and FD30, fusion score, þ þ þ ). When 40 amino acids were removed from the F-tail, we observed complete loss of fusion function (Figure 1b ; FD40, fusion score, À ).
The protein expression levels of the F-tail truncation mutants were analyzed by separating cell lysates from transfected VeroaHis cells and immunobloting with a TPMV F-ectodomain-specific antibody (Figure 2a ; Endo H lanes). These analyses indicated that all the mutants were expressed at or near wild-type levels. Moreover, all mutant proteins retained proteolytic activation of the F 0 precursor to the fusion competent F 1 þ F 2 complex.
To define the minimal functional F-tail, we then shortened the F-tail in two amino-acid increments (Figure 1b ; FD32, FD34, FD36 and FD38). As FD32 was the largest truncation to still maintain wild-type fusion function, we selected this mutant for the generation of a hybrid F protein. This protein consists of the TPMV ectodomain, transmembrane domain and six amino acids of the TPMV F-tail fused to the 33 amino-acid MV F-tail (Figure 2b ; FD32/mvcyt). When this hybrid F protein was coexpressed with the standard TPMV H protein, it supported a slightly reduced level of fusion compared with the parental FD32 mutant (Figure 2b ; fusion score, þ þ ).
TPMV H protein with four-residue cytoplasmic tail maintains wildtype levels of fusion helper function The TPMV H cytoplasmic tail is predicted to be 94 residues in length, B60 residues longer than the MV H-tail. We made progressive truncations of the TPMV H-tail to define the minimal segment necessary for fusion-support function (Figure 3a ; HD10-HD100). Up to 60 residues could be deleted without reducing fusion-support function (Figure 3a ; mutants HD10-HD60, fusion scores, þ þ þ ). Further truncations of 70 or 80 residues inhibited fusion-support function (Figure 3a ; HD70 and HD80, fusion score, þ þ ). However, truncation of 90 residues restored normal function (Figure 3a ; HD90, fusion score, þ þ þ ), whereas a deletion of 100 residues completely inhibited function (Figure 3a ; HD100, fusion score, À ). The second round of truncations to further define the minimal functional H-tail thus included mutants HD92-HD98 (Figure 3a) . With the exception of the HD92 mutant that had strongly reduced fusion-support function (Figure 3a ; HD92, fusion score, þ ), none of the additional mutants were fusion competent (Figure 3a; HD94-HD98) . Therefore, the HD60 and HD90 mutants were considered the most promising for the generation of hybrid protein.
Next, we documented H-protein expression by immunoblot analysis of cell lysates from Vero-aHis cells transfected with the respective H-protein constructs (Figure 3b) . Comparable levels of H-protein expression were documented for HD20, HD30, HD40 and HD60 and wild-type H. In contrast, HD10 and HD50 were expressed at much lower levels while retaining full fusion support, an observation indicating that high expression levels are not required for full function. As HD90 was the largest truncation to have maintained wild-type function and protein expression, we selected this mutant for the generation of a hybrid H protein.
We constructed a hybrid H protein comprised of the ectodomain, transmembrane segment and three residues of the TPMV H-tail (HD90) fused to the 34 amino-acid MV H-tail. The hybrid protein, which was named HD90/mvcyt, supported fusion with slightly reduced efficiency when coexpressed with the wild-type TPMV F protein (fusion score, þ þ , data not shown). However, when HD90/mvcyt was coexpressed with the hybrid F protein, FD32/mvcyt, fusion was below detection levels, indicating that the combination of two-hybrid glycoproteins with slightly reduced fusion efficiency is not a viable option for virus rescue. Sequence of the F protein predicted cytoplasmic tail (CT) and part of the transmembrane (TM) segment; a vertical line separates the two regions. Deletion mutants were named by their extent, such as a deletion of 10 amino acids was named FD10. The fusion efficiency of each construct was tested after coexpression with the standard H His-tag protein. The ectodomain of this protein is extended with a six-histidine-tag, allowing for fusion-support function in Vero-aHis cells, expressing a pseudoreceptor recognizing the His-tag. 23, 28 Fusion efficie levels are denoted on the right using the scale illustrated in panel a. His, histidine.
To promote assembly while mitigating potential interference from the TPMV H protein's bulky cytoplasmic segment, we paired the chimeric FD32/mvcyt with the truncated HD90, and found that this combination supported fusion with only slightly reduced efficiency (Figure 3c ). We did not attempt to make a virus with the HD60 deletion.
A TPMV-shielded hybrid MV propagates poorly We then transferred the genes for the TPMV-MV F-protein hybrid and the truncated TPMV H protein to the MV infectious cDNA, 20, 25 substituting the endogenous genes. We used the vaccine strain vector backbone p( þ )MVvac2(GFP)H, 20 which expresses GFP as a marker protein, and named the hybrid virus MVvac2(FD32/mvcyt-HD90)GFP. This virus was recovered using the helper cell line 293-3-46, followed by propagation on Vero-aHis cells. 23, 25, 28 Green fluorescent infectious centers were observed in multiple experiments, and propagated for several passages. Following each passage cytopathic effect increased, until up to 80% of the cells were in syncytia. At this point, virus stocks were harvested, but found to have low titers usually ranging from 10 3 to 10 4 TCID 50 per ml during early passages. Virus titer did not increase at late passages.
Nevertheless, we characterized the growth kinetics of the hybrid virus and compared it with the two parental viruses, MVvac2(GFP)H and TPMV (Figure 4) . Titers of TPMV particles released from tupaia baby fibroblast cells reached 10 6 TCID 50 per ml, with a 10-fold lower titer documented for cell-associated virus (Figure 4a ). As expected, MV infectivity in Vero-aHis cells was predominantly cell-associated with titers reaching 10 6 TCID 50 per ml, and cell-free titers approximately 10-fold lower (Figure 4b ; filled symbols). However, growth analysis of the hybrid virus on Vero-aHis cells (Figure 4b ; open symbols) revealed low intracellular titers of only 10 2 TCID 50 per ml, and even lower extracellular titers.
Deletion of the TPMV H-protein cytoplasmic tail does not affect intracellular transport As truncation of the cytoplasmic tail may affect intracellular transport, and thus particle assembly, we next characterized the efficiency of glycoprotein transport and processing. 5, 31 We first compared surface expression of wild-type TPMV-H and HD90, and found low but comparable expression of the wild-type and the truncated H proteins on the surface of Vero-aHis cells ( Figure 5 ; Vero-aHis column). A control cell line known to have optimal vesicular transport, CHO-K1, efficiently expressed both wild-type H and the truncated HD90 proteins at the cell surface ( Figure 5 , CHO-K1 column).
To more precisely compare intracellular transport of the wildtype and truncated H proteins, we performed pulse-chase experiments to measure the acquisition of EndoH-resistant glycans by the H protein over time. The acquisition of EndoH resistance indicates conversion of high mannose glycans to hybrid and complex oligosaccharides following processing through the medial-Golgi apparatus. 32 We determined that 50% of the H proteins acquired EndoH resistance within 3 h, reflecting transport through the medial-Golgi (Figures 6a and c; diamonds) . A similar rate of transport was observed for HD90 (Figures 6b and c;  squares) . Thus, the truncation of the H-protein cytoplasmic tail does not hinder intracellular transport.
Modification of the TPMV F-protein tail affects proteolytic activation We compared proteolytic activation of the wild-type and chimeric TPMV F proteins by measuring the kinetics of F 0 cleavage by pulse-chase experiments. The efficiency of protein activation was determined by comparing the intensities of the F 0 and F 1 bands at different time points after adjusting for differences in signal intensities resulting from differential radiolabeled incorporation between F 0 and F 1 . We found that about 50% of the wild-type F protein was activated in 6 h (Figures 7a and c) , whereas approximately 25% of FD32/mvcyt was activated during the same time period (Figures 7b and c) . Thus, slow proteolytic processing of the hybrid F protein may contribute to inefficient particle production.
DISCUSSION
Antibody-mediated neutralization interferes with the efficacy of systemic virotherapy. To avoid MV-neutralizing antibodies, we previously shielded the MV nucleocapsid with the envelope glycoproteins from the related Morbillivirus canine distemper virus, and showed that this hybrid virus retains oncolytic efficacy. 10 To avoid the neutralizing response against the hybrid virus, and allow for sequential cycles of therapy, shielded viruses that are not crossreactive with either the MV or canine distemper virus glycoproteins are required. As all of the well-characterized members of the Morbillivirus genus are crossreactive with one of these envelopes, we explored the suitability of the glycoproteins from the related TPMV for particle assembly. While a simple exchange of the MV and TPMV glycoproteins did not support virus rescue, but the combination of a hybrid F protein, including the MV F cytoplasmic tail and a TPMV H protein with a truncated cytoplasmic tail, did allow rescue. However, infectivity production was minimal: while we occasionally observed titers in the 10 5 -10 6 TCID 50 per ml in fresh supernatants, these titers dropped to 10 3 or lower after freeze-thawing. In practice, infectivity could be propagated only by cell fusion, limiting applications for oncolytic therapy.
We think that improper particle assembly is the limiting factor for the generation of stable particles of shielded MV: viral particles may not form properly, or be unstable and fall apart after release from the cell. This implies that detailed information about the interactions required for MV particle assembly is necessary to design hybrid glycoproteins that better retain their fusion or fusion-support function. While the feasibility of envelope exchanges between members of the same Paramyxovirus genus is established, [33] [34] [35] and in one case glycoprotein exchange between viruses of different genera was successful when based on hybrid glycoproteins, 36 recent systematic studies have documented significant losses of fusion function for many hybrids' paramyxovirus F proteins. 37 Analogously, we observed here that the TPMV-MV hybrid F protein lost some fusion function.
Consistently with proposed multiple interactions between F and H at cell fusion, this negative effect was amplified when the hybrid F protein was expressed in combination with an H protein with a truncated cytoplasmic tail.
A promising strategy to adapt new shielding envelopes on oncolytic MV relies on the glycoproteins of recently characterized viruses 38, 39 and potential viruses. 40 Those kinds are more closely related to Morbilliviruses than TPMV, and their glycoproteins may be more easily adaptable to the MV nucleocapsid. In particular, we are exploring whether the glycoproteins of feline morbillivirus, a very recently characterized member of the Morbillivirus genus, 41 retain efficient function and particle assembly, while at the same time not crossreacting.
Having observed inefficient glycoprotein transport in Vero-aHis cells, we have tested other cell lines expressing anti-His-tag pseudoreceptors as candidate hosts for virus rescue. These cell lines include 293 H6, 42 U118MG-HissFv.rec 43, 44 and CHO-aHis, 23 which have been used for the rescue of other viruses. Both U118MG-HissFv.rec 43, 44 and CHO-aHis 23 transport MV and TPMV H Figure 6 . Wild-type and truncated Tupaia paramyxovirus (TPMV) hemagglutinin (H)-protein transport kinetics. CHO-K1 cells were transfected with wild-type fusion (F) and (a) H His-tag or (b) HD90 or an empty vector (mock) for 24 h before being starved for 30 min and pulsed with 100 mCi ml 35 S-labeled methionine and cysteine for 1 h and then chased for up to 4 h. After the indicated chase period, cell lysates were collected and H protein was immunoprecipitated and digested without or with endo-b-N-acetylglycosaminidase H (EndoH) ( À / þ lanes, respectively), followed by fractioning on 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). (c) Kinetics of complex oligosaccharide acquisition. Vertical axis: percent EndoH resistance of three experiments for wild-type H (diamonds) and HD90 (squares). Horizontal axis: time of chase (h). His, histidine. with approximately three times greater efficiency than Vero-aHis (data not shown). As the former cells are of human origin, they may be better hosts for the recovery of shielded recombinant MV than Vero-aHis cells.
Finally, truncated TPMV glycoproteins have recently been utilized for the shielding of lentivirus-based vectors, 15 specifically FD32-and HD80-truncated mutants to package effectively lentiviral capsids. 15 We note that the lentiviral gag-protein contains sequences that promote budding referred to as late domains, 45, 46 and that these capsids do not depend on specific interactions for budding. This mechanism may mitigate the effects of the reduced fusion phenotype on infectivity and particle production. In contrast to the lentiviral system, late domains have not been identified in MV proteins.
